ABCB4 and Hepatic fibrosis: Additionally, administration of S63845, a proapoptotic BH3-mimetic therapy, significantly reduced the DR-cell population and markers of inflammation and liver fibrosis in Mdr2–/– mice, while targeted removal of senescent cholangiocytes via AP20187 or fisetin leads to a reduction in the expression of inflammatory, fibrotic, and senescence markers associated with the disease [17, 192].